TNBC Subtype Classification via Gene Expression Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Triple-negative breast cancer (TNBC) treatment is challenging due to its heterogeneity and lack of well-defined molecular targets, leading to poor prognosis and limited effective treatments.
Innovation Solution
The development of methods to determine TNBC subtypes based on gene expression profiles, allowing for personalized treatment protocols and predicting the effectiveness of specific treatments by identifying increased expression of specific genes associated with each subtype.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional chemotherapy is used for TNBC treatment, then some patients show clinical response, but the treatment lacks precision due to disease heterogeneity and results in poor prognosis with high recurrence rates
Solution Approach 1:
The patent segments TNBC into six distinct molecular subtypes (BL1, BL2, IM, M, MSL, LAR) based on gene expression profiles. Each subtype is characterized by specific gene signatures and biological features, enabling differentiated treatment approaches. For example, BL1 tumors with high cell cycle gene expression are treated differently from LAR tumors with hormone-regulated gene expression, resolving the contradiction between maintaining broad treatment efficacy and achieving personalized adaptation.
Solution Approach 2:
The patent changes the treatment parameter from uniform chemotherapy to subtype-specific targeted therapy based on gene expression parameters. By measuring expression levels of specific gene sets (e.g., cell cycle genes for BL1, immune signaling genes for IM), the treatment approach is adjusted to match the molecular characteristics of each subtype, thereby improving both reliability and adaptability simultaneously.
2Ease of operation
If uniform chemotherapy protocols are applied to all TNBC patients, then treatment simplicity is maintained, but treatment precision is lost due to ignoring molecular heterogeneity
Solution Approach 1:
The patent replaces the mechanical/simple approach of uniform chemotherapy with a molecular-based classification system using gene expression profiling. Instead of applying the same treatment to all patients, the system uses molecular markers (gene expression signatures) to identify six distinct TNBC subtypes, each with specific treatment recommendations. This substitution maintains ease of operation through standardized gene expression assays while dramatically improving measurement precision in characterizing tumor biology.
3Device complexity
If TNBC is treated as a homogeneous disease, then treatment planning is simplified, but clinical outcomes deteriorate due to lack of targeted therapy for specific molecular subtypes
Solution Approach 1:
The patent divides TNBC into six molecular subtypes (BL1, BL2, IM, M, MSL, LAR) with distinct gene expression signatures and biological characteristics. Each subtype has specific treatment implications: BL1 tumors respond to DNA-damaging agents, IM tumors may benefit from immunotherapy, and LAR tumors show sensitivity to hormone therapies. This segmentation improves clinical prognosis by enabling targeted therapy selection while managing complexity through standardized gene expression-based classification.
Solution Approach 2:
The patent changes the treatment parameter from uniform chemotherapy to subtype-specific targeted therapy based on gene expression parameters. By measuring expression levels of specific gene sets (e.g., cell cycle genes for BL1, immune signaling genes for IM), the treatment approach is adjusted to match the molecular characteristics of each subtype, thereby improving both reliability and adaptability simultaneously.
Data Source
AI summary
In one aspect provided herein are methods of determining a triple negative breast cancer (TNBC) subtype in an individual in need thereof comprising determining expression of one or more genes in one or more TNBC cells of the individual; and comparing the expression of the one or more genes in the TNBC cells with the expression of the one or more genes in a control. In another aspect, the methods are directed to determining a treatment protocol for the TNBC patient based on the TNBC subtype. In another aspect, the methods are directed to predicting whether an individual will benefit from a treatment for a particular TNBC subtype. In yet another aspect, the invention is directed to a method of determining whether an agent can be used to treat a TNBC subtype.